{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:09:52Z","timestamp":1772827792446,"version":"3.50.1"},"reference-count":60,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12395","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:40:40Z","timestamp":1705585240000},"source":"Crossref","is-referenced-by-count":1,"title":["CX\u20115461 potentiates imatinib\u2011induced apoptosis in K562 cells by stimulating <i>KIF1B<\/i> expression"],"prefix":"10.3892","volume":"27","author":[{"given":"Chaochao","family":"Dai","sequence":"first","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Cui","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Gao","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"key20240227085757_b1-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/0145-2126(95)00057-7","article-title":"BCR\/ABL and leukemia","volume":"20","author":"Butturini","year":"1996","journal-title":"Leuk Res"},{"key":"key20240227085757_b2-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann Intern Med"},{"key":"key20240227085757_b3-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1349-7006.2012.02346.x","article-title":"Molecular biology of chronic myeloid leukemia","volume":"103","author":"Maru","year":"2012","journal-title":"Cancer Sci"},{"key":"key20240227085757_b4-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20240227085757_b5-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20240227085757_b6-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"key20240227085757_b7-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240227085757_b8-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"key20240227085757_b9-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2016.1272682","article-title":"Induction of p53 suppresses chronic myeloid leukemia","volume":"58","author":"Peterson","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"key20240227085757_b10-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"key20240227085757_b11-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0145-2126(95)00024-i","article-title":"Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis","volume":"19","author":"Guinn","year":"1995","journal-title":"Leuk Res"},{"key":"key20240227085757_b12-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/10428199409114155","article-title":"Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia","volume":"16","author":"Marasca","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"key20240227085757_b13-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s0165-4608(96)00413-x","article-title":"p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis","volume":"98","author":"Stuppia","year":"1997","journal-title":"Cancer Genet Cytogenet"},{"key":"key20240227085757_b14-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.3109\/10428199309047856","article-title":"The cytogenetic scenario of chronic myeloid leukemia","volume":"11 (Suppl 1)","author":"Mitelman","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"key20240227085757_b15-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: Oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"e2955","key":"key20240227085757_b16-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.346","article-title":"WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response","volume":"8","author":"Janczar","year":"2017","journal-title":"Cell Death Dis"},{"issue":"eaar2036","key":"key20240227085757_b17-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar2036","article-title":"Development of a stress response therapy targeting aggressive prostate cancer","volume":"10","author":"Nguyen","year":"2018","journal-title":"Sci Transl Med"},{"key":"key20240227085757_b18-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.molcel.2010.09.024","article-title":"The nucleolus under stress","volume":"40","author":"Boulon","year":"2010","journal-title":"Mol Cell"},{"key":"key20240227085757_b19-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4161\/nucl.32235","article-title":"Nucleolar stress with and without p53","volume":"5","author":"James","year":"2014","journal-title":"Nucleus"},{"key":"key20240227085757_b20-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res"},{"key":"key20240227085757_b21-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2016-05-718171","article-title":"Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population","volume":"129","author":"Hein","year":"2017","journal-title":"Blood"},{"key":"key20240227085757_b22-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"key20240227085757_b23-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-d","article-title":"Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line","volume":"17","author":"Law","year":"1993","journal-title":"Leuk Res"},{"key":"key20240227085757_b24-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2141.2002.03468.x","article-title":"p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases","volume":"117","author":"Di Bacco","year":"2002","journal-title":"Br J Haematol"},{"key":"key20240227085757_b25-ETM-27-3-12395","first-page":"839","article-title":"p53 in chronic myeloid leukemia cell lines","volume":"6","author":"Bi","year":"1992","journal-title":"Leukemia"},{"key":"key20240227085757_b26-ETM-27-3-12395","first-page":"315","article-title":"p53-mediated differentiation of the erythroleukemia cell line K562","volume":"11","author":"Chylicki","year":"2000","journal-title":"Cell Growth Differ"},{"key":"key20240227085757_b27-ETM-27-3-12395"},{"key":"key20240227085757_b28-ETM-27-3-12395"},{"issue":"e00149","key":"key20240227085757_b29-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"key20240227085757_b30-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"key20240227085757_b31-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1042\/BST20140050","article-title":"RBFOX2 protein domains and cellular activities","volume":"42","author":"Arya","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"key20240227085757_b32-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/onc.2013.50","article-title":"The RNA-binding protein Rbfox2: An essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion","volume":"33","author":"Braeutigam","year":"2014","journal-title":"Oncogene"},{"issue":"77","key":"key20240227085757_b33-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0114-3","article-title":"RBFOX2 and alternative splicing in B-cell lymphoma","volume":"8","author":"Quentmeier","year":"2018","journal-title":"Blood Cancer J"},{"key":"key20240227085757_b34-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"24426","DOI":"10.1074\/jbc.M802316200","article-title":"KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death","volume":"283","author":"Munirajan","year":"2008","journal-title":"J Biol Chem"},{"key":"key20240227085757_b35-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1101\/gad.1648608","article-title":"The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor","volume":"22","author":"Schlisio","year":"2008","journal-title":"Genes Dev"},{"key":"key20240227085757_b36-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"34229","DOI":"10.18632\/oncotarget.8748","article-title":"XAF1 promotes neuroblastoma tumor suppression and is required for KIF1B\u03b2-mediated apoptosis","volume":"7","author":"Choo","year":"2016","journal-title":"Oncotarget"},{"key":"key20240227085757_b37-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.devcel.2015.12.029","article-title":"The 1p36 tumor suppressor KIF 1B\u03b2 is required for calcineurin activation, controlling mitochondrial fission and apoptosis","volume":"36","author":"Li","year":"2016","journal-title":"Dev Cell"},{"key":"key20240227085757_b38-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/mc.22997","article-title":"Tumor suppressor KIF1B\u03b2 regulates mitochondrial apoptosis in collaboration with YME1L1","volume":"58","author":"Ando","year":"2019","journal-title":"Mol Carcinog"},{"key":"key20240227085757_b39-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2159-8290.CD-13-0362","article-title":"RNA helicase A is a downstream mediator of KIF1B\u03b2 tumor-suppressor function in neuroblastoma","volume":"4","author":"Chen","year":"2014","journal-title":"Cancer Discov"},{"key":"key20240227085757_b40-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mc.22919","article-title":"The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing","volume":"58","author":"Gordon","year":"2019","journal-title":"Mol Carcinog"},{"key":"key20240227085757_b41-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/156800907780618293","article-title":"The kinase inhibitor imatinib-an immunosuppressive drug?","volume":"7","author":"Wolf","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"266","key":"key20240227085757_b42-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020266","article-title":"Targeting the RNA polymerase I transcription for cancer therapy comes of age","volume":"9","author":"Ferreira","year":"2020","journal-title":"Cells"},{"key":"key20240227085757_b43-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"49800","DOI":"10.18632\/oncotarget.10452","article-title":"Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM\/ATR signaling","volume":"7","author":"Quin","year":"2016","journal-title":"Oncotarget"},{"issue":"zcaa032","key":"key20240227085757_b44-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa032","article-title":"The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability","volume":"2","author":"Mars","year":"2020","journal-title":"NAR Cancer"},{"issue":"14432","key":"key20240227085757_b45-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14432","article-title":"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours","volume":"8","author":"Xu","year":"2017","journal-title":"Nat Commun"},{"key":"key20240227085757_b46-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1073\/pnas.1921649117","article-title":"The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning","volume":"117","author":"Bruno","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"100968","key":"key20240227085757_b47-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia-What to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"key":"key20240227085757_b48-ETM-27-3-12395","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"key20240227085757_b49-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","article-title":"The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer","volume":"124","author":"Yan","year":"2021","journal-title":"Br J Cancer"},{"issue":"110906","key":"key20240227085757_b50-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110906","article-title":"Combined inhibition of RNA polymerase I and mTORC1\/2 synergize to combat oral squamous cell carcinoma","volume":"133","author":"Shi","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"key20240227085757_b51-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-14-0673","article-title":"Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma","volume":"6","author":"Devlin","year":"2016","journal-title":"Cancer Discov"},{"key":"key20240227085757_b52-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","article-title":"CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition","volume":"20","author":"Lawrence","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20240227085757_b53-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-16-0124","article-title":"The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer","volume":"22","author":"Rebello","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4059","key":"key20240227085757_b54-ETM-27-3-12395","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07928-4","article-title":"CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I","volume":"12","author":"Lehman","year":"2022","journal-title":"Sci Rep"},{"key":"key20240227085757_b55-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-Human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: Results of a phase I dose-escalation study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov"},{"key":"key20240227085757_b56-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/humu.22719","article-title":"The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing","volume":"36","author":"Lindqvist","year":"2015","journal-title":"Hum Mutat"},{"key":"key20240227085757_b57-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/onc.2010.22","article-title":"Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma","volume":"29","author":"Ochiai","year":"2010","journal-title":"Oncogene"},{"key":"key20240227085757_b58-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"120","DOI":"10.18632\/oncotarget.1337","article-title":"MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia","volume":"5","author":"Astolfi","year":"2014","journal-title":"Oncotarget"},{"key":"key20240227085757_b59-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jpedsurg.2019.02.028","article-title":"Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression","volume":"54","author":"Taylor","year":"2019","journal-title":"J Pediatr Surg"},{"key":"key20240227085757_b60-ETM-27-3-12395","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jim.2005.07.012","article-title":"Evaluation of CML model cell lines and imatinib mesylate response: Determinants of signaling profiles","volume":"305","author":"Wetzel","year":"2005","journal-title":"J Immunol Methods"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:58:06Z","timestamp":1709017086000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12395","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"article-number":"107"}}